key: cord-0979516-f455bxh2
authors: nan
title: QUM and COVID-19 in young adults
date: 2020-08-03
journal: Aust Prescr
DOI: 10.18773/austprescr.2020.038
sha: f17ace087df3f2e6c6ee7a3586975e6f666edfbc
doc_id: 979516
cord_uid: f455bxh2

nan

I read the editorial on COVID-19 and the quality use of medicines 1 with great interest and found it very balanced and rational. I liked the approach of the editorial.

I have a question -can COVID-19 treatment be left to antipyretic and other symptomatic treatment for young adults with no comorbidities and taking other precautions such as isolation? Are there any studies reported? Is experimental prescribing with hydroxychloroquine, antivirals and antibiotics absolutely necessary? In the early phase of the pandemic, many patients with mild disease might have self-treated or were medically treated as if they had flu and came out of it in 4-5 days without knowing that it was COVID. Their immune system must have worked well. These questions are important, but the harms and benefits of these treatments for COVID-19 in this age group are poorly defined.

It is increasingly clear that the natural history of COVID-19 reflects risk factors whereby younger age and fewer comorbidities are favourable. 1-3 For example, despite a high number of cases of adults under 50 years of age in Australia, only 7% were hospitalised and 0.03% died. 4 In India, mortality has been reported as 0.4% in those under 40 years of age. 5 Randomised controlled trials are needed to quantify the efficacy of antiviral treatments for reducing COVID-19 disease progression. 6 To our knowledge there are no trials in young adults with mild disease. However, death and other adverse effects to antivirals in COVID-19 have been reported, but mostly in patients with severe disease so the observation may be confounded by indication. 7 Therefore, more data are required to confirm the safety and efficacy of antivirals in lower severity COVID-19. In Australia, the use of antiviral treatments outside a clinical trial is not recommended 8 and we support this.

It seems reasonable to assume that general health advice for other mild infections, as described by Manjiri Gharat, also apply in COVID-19. We are not aware of data supporting a benefit of antipyretics in COVID-19. However, some authors have questioned their safety in COVID-19 including paracetamol-associated acute hepatitis 9 and non-steroidal anti-inflammatory drugassociated systemic infection. 10 These risks appear theoretical so are insufficient to advise against the use of antipyretics, but more data are required.

The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by any responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China

COVID-19 National Incident Room Surveillance Team. COVID-19

Average age of India's Covid deaths 60; diabetes, BP common co-ailments. The Times of India

COVID-19 and the quality use of medicines: evidence, risks and fads

Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review

National COVID-19 Clinical Evidence Taskforce. Caring for people with COVID-19. Living guidelines

Gastroenterologists, hepatologists, COVID-19 and the use of acetaminophen

Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection